Granted Patent
B2
US 10,441,644 · App. 15/613,837 · Granted Oct 15, 2019
H3.3 CTL peptides and uses thereof
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.
Claims (4)
1. A T-cell expressing one or more polypeptides comprising a T-cell receptor (TCR) or fragment thereof that binds to a peptide/major histocompatibility complex (MHC) complex, wherein the peptide in the peptide/MHC complex consists of 10-12 amino acids and comprises (R/A)MSAP(S/A)TGGV (SEQ ID NO:1).
2. The T-cell of claim 1 , wherein the TCR or fragment thereof is heterologous to the T-cell.
3. The T-cell of claim 1 , wherein expression of the TCR or fragment thereof is under the control of a heterologous promoter.
4. The T-cell of claim 1 , wherein the peptide consists of RMSAPSTGGV (SEQ ID NO:2).
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 22, 2019
From: OKADA, HIDEHO; HOU, YAFEI
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 050140/0963 →
CONFIRMATORY LICENSE
Recorded Jun 14, 2017
From: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042806/0801 →
Continuity (4)
Continuation In Part
PCTUS2016030849
· May 4, 2016
Provisional Application
62157362
· May 5, 2015
Provisional Application
62212508
· Aug 31, 2015